stockrow
Friday 6 November 2026
Export FEMY’s income statement to Excel — free account
Femasys Inc.
FEMY Healthcare Medical Instruments & Supplies
Femasys Inc.’s revenue for fiscal 2025 (year ended December 2025) was $2.3 million, up 40.8% from fiscal 2024.
- Revenue
- −18.9%
- EPS
- +58.4%
- Free cash flow
- +11.3%
- Total debt
- +3,369.3%
Quarter to June 2026, against a year earlier
1.32
0.12
−8.33%
Follow FEMY
Alert me
Target Price Range
Analyst price targets
Free accountTen years at a glance Fiscal years to December
| Ten-year view | Analyst estimates Powerpack | |||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Group | Line | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | TTM Jun ’26 | Trend | 10 yrs | 2026e | 2027e | 2028e | Next 3/yr |
| Income, $m | ||||||||||||||||||
| Income, $m | Revenue | — | — | — | 1 | 1 | 1 | 1 | 1 | 2 | 2 | 2 | +16.3% | 2 | 9 | 20 | +105.2% | |
| Gross margin, % | — | — | — | (41.89) | 70.47 | 68.60 | 63.36 | 64.54 | 66.55 | 61.96 | 60.95 | +103.9 pt | ||||||
| EBT | — | — | — | (11) | (7) | (8) | (11) | (14) | (19) | (19) | (12) | +8.7% | ||||||
| EBT margin, % | — | — | — | (1,212.88) | (666.08) | (638.62) | (944.11) | (1,328.62) | (1,154.44) | (812.22) | (511.49) | +400.7 pt | ||||||
| Net income | — | 0 | — | (11) | (7) | (8) | (11) | (14) | (19) | (19) | (12) | n/m | ||||||
| Per share, $ | ||||||||||||||||||
| Per share, $ | Revenue | — | — | — | 0.08 | 21.62 | 3.52 | 2.04 | 1.39 | 1.46 | 1.16 | 0.69 | +56.5% | |||||
| Earnings | — | — | — | (0.96) | (144.06) | (22.40) | (19.20) | (18.60) | (17.00) | (9.40) | (4.58) | +46.3% | ||||||
| Cash flow | — | — | — | (0.94) | (102.77) | (23.63) | (18.17) | (14.67) | (17.46) | (9.45) | (5.26) | +47.0% | ||||||
| Capex | — | — | — | 0.00 | (0.66) | (0.91) | (0.69) | (0.19) | (0.68) | (0.27) | (0.13) | n/m | ||||||
| Free cash flow | — | — | — | (0.94) | (103.43) | (24.55) | (18.85) | (14.85) | (18.15) | (9.72) | (5.38) | +47.7% | ||||||
| Book value | — | — | — | (3.86) | (1,079.49) | 78.46 | 25.80 | 23.86 | 2.07 | 2.97 | 1.20 | n/m | ||||||
| Shares, m | — | — | — | 12 | 0 | 0 | 1 | 1 | 1 | 2 | 3 | (25.7%) | ||||||
| Valuation, × | ||||||||||||||||||
| Valuation, × | P/E | — | — | — | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.0 | |||||
| P/S | — | — | — | 10.79 | 10.79 | 22.19 | 8.82 | 20.22 | 15.04 | 15.86 | 1.93 | 14.8 | ||||||
| P/B | — | — | — | 0.00 | 0.00 | 0.99 | 0.70 | 1.18 | 10.63 | 6.20 | 1.10 | 2.8 | ||||||
| EV/Sales | — | — | — | 60.75 | 60.75 | 1.32 | (1.81) | 4.05 | 13.00 | 14.13 | 2.87 | 21.7 | ||||||
| EV/FCF | — | — | — | (11.04) | (11.04) | (0.19) | 0.20 | (0.38) | (1.05) | (1.69) | (0.37) | (3.6) | ||||||
| Cash, $m | ||||||||||||||||||
| Cash, $m | Operating cash flow | — | — | — | (11) | (5) | (8) | (11) | (11) | (19) | (19) | (18) | +9.2% | |||||
| Capex | — | — | — | (1) | 0 | 0 | 0 | 0 | (1) | (1) | 0 | (4.6%) | ||||||
| Free cash flow | — | — | — | (11) | (5) | (8) | (11) | (11) | (20) | (19) | (18) | +9.7% | ||||||
| Balance, $m | ||||||||||||||||||
| Balance, $m | Working capital | — | — | — | 7 | 1 | 24 | 13 | 20 | (1) | 13 | 4 | +11.3% | |||||
| Net debt | — | — | — | 50 | (2) | (25) | (13) | (17) | (3) | (4) | 2 | n/m | ||||||
| Shareholders’ equity | — | — | — | (45) | (52) | 26 | 15 | 18 | 2 | 6 | 4 | n/m | ||||||
| Returns, % | ||||||||||||||||||
| Returns, % | ROA | — | — | — | (89.13) | (90.91) | (41.66) | (50.11) | (63.81) | (93.61) | (112.32) | (94.25) | (23.2) pt | |||||
| ROIC | — | — | — | 0.00 | 0.00 | (303.27) | (299.29) | (893.46) | 0.00 | (578.36) | (176.91) | (578.4) pt | ||||||
| ROE | — | — | — | 24.83 | 13.34 | 59.12 | (54.81) | (84.82) | (182.18) | (455.80) | (443.65) | (480.6) pt | ||||||
| People | ||||||||||||||||||
| People | Employees | — | — | — | — | 26 | 29 | 36 | 34 | 71 | 54 | — | +15.7% | |||||
| Revenue/emp, $m | — | — | — | 0.00 | 0.04 | 0.04 | 0.03 | 0.03 | 0.02 | 0.04 | — | n/m | ||||||
Negative figures in brackets.
estimates
Fiscal years to Dec 2025 · latest quarter Jun 2026 · fundamentals updated 26 Oct 2026
Femasys Inc. vs peers in Medical Instruments & Supplies (Q) = latest quarter vs a year earlier
| Company | Market cap | P/E | Fwd P/E | Revenue growth (Q) | EPS growth (Q) | FCF growth (Q) | Gross margin (Q) | EBIT margin (Q) | Compare |
|---|---|---|---|---|---|---|---|---|---|
| MLSS Milestone Scientific, Inc. | $27.1M | — (loss-making) | — (loss-making) | +22.27% (above 0%: growing) | n/m | +66.68% (above 0%: growing) | 67.24% | (37.37%) | Compare |
| RVP Retractable Technologies, Inc. | $16.9M | — (loss-making) | 11.1× | −31.07% (below 0%: shrinking) | n/m | +56.67% (above 0%: growing) | 2.65% | (71.46%) | Compare |
| BNGO Bionano Genomics, Inc. | $15.4M | — (loss-making) | — (loss-making) | +21.36% (above 0%: growing) | n/m | −33.93% (below 0%: shrinking) | 52.80% | (88.34%) | Compare |
| NXGL NexGel, Inc. | $12.7M | — (loss-making) | — (loss-making) | +27.81% (above 0%: growing) | n/m | −432.32% (below 0%: shrinking) | 30.09% | (67.96%) | Compare |
| FEMY Femasys Inc. | $11.0M | — (loss-making) | — (loss-making) | −18.93% (below 0%: shrinking) | n/m | +11.29% (above 0%: growing) | 57.08% | (1,526.79%) | |
| CUPR Cuprina Holdings (Cayman) Limited | $10.4M | — | — | — | — | — | — | — | Compare |
| RGNT Regentis Biomaterials Ltd. | $8.2M | — | — | — | — | −132.79% (below 0%: shrinking) | — | — | Compare |
| LUCY Innovative Eyewear, Inc. | $7.2M | — (loss-making) | — | +74.46% (above 0%: growing) | n/m | +9.61% (above 0%: growing) | 24.00% | (168.73%) | Compare |
| MHUAF Meihua International Medical Technologies Co., Ltd. | $4.3M | — | — | — | — | −61.55% (below 0%: shrinking) | 35.48% | 0.00% | Compare |
| Median of peers | $11.5M | — | — | +22.27% | — | −33.93% | 32.79% | (69.71%) |
Pay and ownership Proxy statement filed 30 April 2026
Ownership
Directors and executive officers, together
7.75%
Dauntless Investment Group, LLC
9.99%
Jorey Chernett
9.99%
PharmaCyte Biotech, Inc.
7.63%
Ownership is the proxy’s own table: the directors and officers as a group, and every holder of 5% or more.
Read the proxy statement